Different Laboratory Abnormalities in COVID-19 Patients with Hypertension or Diabetes

Xiaojun Wu,Tong Wang,Yilu Zhou,Xiaofan Liu,Hong Zhou,Yang Lu,Weijun Tan,Mingli Yuan,Xuhong Ding,Jinjing Zou,Ruiyun Li,Hailing Liu,Rob M. Ewing,Yi Hu,Hanxiang Nie,Yihua Wang
DOI: https://doi.org/10.1007/s12250-020-00296-1
IF: 6.947
2020-01-01
Virologica Sinica
Abstract:We reported recently that hypertension is a risk factor for severe cases of COVID-19, independent of age and other variables (Liu et al. 2020a). An important question is why patients with hypertension and diabetes yield poorer clinical outcomes than those without. Human pathogenic coronavirus SARS-CoV-2 utilizes angiotensin-converting enzyme 2 (ACE2) as a receptor for viral cell entry. Since the levels of ACE2 are substantially increased in patients with hypertension or diabetes, who are treated with ACE inhibitors (ACEIs) and angiotensin Ⅱ type-Ⅰ receptor blockers (ARBs) (Ferrario et al. 2005), Fang and colleagues hypothesized that ACE2-stimulating drugs could potentially increase the risk of developing severe COVID-19 (Fang et al. 2020). This was not supported by a recent study led by Dr. Reynolds (Reynolds et al. 2020), whose analysis showed no positive association for ACEIs or ARBs for either the risk of SARS-CoV-2 infection or severe illness (Reynolds et al. 2020). What else might explain the poorer clinical outcomes of COVID-19 patients with hypertension or diabetes?To explore this question, we re-analysed the same cohort of 99 COVID-19 patients discharged from the general wards of Renmin Hospital of Wuhan University between 5 February 2020 and 14 March 2020 (Ethics approval No: WDRY2020-K124) (Liu et al. 2020a, b).
What problem does this paper attempt to address?